WuXi Biologics is expected to deliver faster sales growth and higher margins this year. Click here to find out why I upgraded ...

The global biologics contract development and manufacturing organization (cdmo) market size is estimated to grow by USD 16.32 ...

Hong Kong stocks rebounded from a four-month low after China’s securities regulator pledged to stabilise the market after a wobbly start to the year. The Hang Seng Index rose 1.4 per cent to 19,141.13 ...

WuXi AppTec announced late yesterday that the Shanghai-based company had pared its stake in WuXi XDC Cayman through two block ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Wuxi Biologics Co. Ltd. is licensing a preclinical trispecific T-cell engager to Candid Therapeutics Inc. in a deal worth up to $925 million plus royalties.

The transaction is expected to close in the first half of 2025, subject to the satisfaction of customary closing conditions.

JPMorgan upgraded Wuxi Biologics (WXXWY) to Overweight from Neutral with a price target of HK$20, up from HK$13, citing expected order growth and improved margins. Although the newsthat WuXi Bio ...

Wuxi Biologics (WXXWY) plans to sell its Irish vaccine facility to Merck (MRK) for around $500M ahead of potential U.S. legislation that would limit business for Chinese biotech companies ...